• 1
    Walport MJ. Complement: first of two parts. N Engl J Med 2001; 344: 105866.
  • 2
    Gal P, Ambrus G, Zavodszky P. C1s, the protease messenger of C1: structure, function and physiological significance. Immunobiology 2002; 205: 38394.
  • 3
    Amano MT, Ferriani VP, Florido MP, Reis ES, Delcolli MI, Azzolini AE, et al. Genetic analysis of complement C1s deficiency associated with systemic lupus erythematosus highlights alternative splicing of normal C1s gene. Mol Immunol 2008; 45: 1693702.
  • 4
    Dragon-Durey MA, Quartier P, Fremeaux-Bacchi V, Blouin J, de Barace C, Prieur AM, et al. Molecular basis of a selective C1s deficiency associated with early onset multiple autoimmune diseases. J Immunol 2001; 166: 76126.
  • 5
    Endo Y, Kanno K, Takahashi M, Yamaguchi K, Kohno Y, Fujita T. Molecular basis of human complement C1s deficiency. J Immunol 1999; 162: 21803.
  • 6
    Inoue N, Saito T, Masuda R, Suzuki Y, Ohtomi M, Sakiyama H. Selective complement C1s deficiency caused by homozygous four-base deletion in the C1s gene. Hum Genet 1998; 103: 4158.
  • 7
    Abe K, Endo Y, Nakazawa N, Kanno K, Okubo M, Hoshino T, et al. Unique phenotypes of C1s deficiency and abnormality caused by two compound heterozygosities in a Japanese family. J Immunol 2009; 182: 16818.
  • 8
    Praz F, Halbwachs L, Lesavre P. Genetic aspects of complement and glomerulonephritis. Adv Nephrol Necker Hosp 1984; 13: 27196.
  • 9
    Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19: 569.
  • 10
    Carroll MC. A protective role for innate immunity in autoimmune disease. Clin Immunol 2000; 95: S308.
  • 11
    Mitchell DA, Taylor PR, Cook HT, Moss J, Bygrave AE, Walport MJ, et al. Cutting edge: C1q protects against the development of glomerulonephritis independently of C3 activation. J Immunol 1999; 162: 56769.
  • 12
    Wallis R, Dodds AW, Mitchell DA, Sim RB, Reid KB, Schwaeble WJ. Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway. J Biol Chem 2007; 282: 784451.
  • 13
    Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006; 17: 172434.
  • 14
    Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006; 148: 6237.
  • 15
    Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009; 9: 1025.